A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients with Type 2 Diabetes Mellitus
Phase 3
Recruiting
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-jRCT2080221754
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Participants who have had a diagnosis of type 2 diabetes mellitus before screening
-Participants who have been OAM-naive (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week washout period prior to randomization
-Participants who are OAM naive with screening glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%.
-Participants who have a body mass index (BMI) of 18.5kg/m2 to 35.0kg/m2
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method